infect
treplet
haploident
transplant
highdos
cyclophosphamid
graftversushost
diseas
prophylaxi
transpl
infect
di
right
reserv
abstract
background
recent
platform
tcell
replet
haploident
hematopoiet
stem
cell
transplant
haplohsct
use
posttranspl
cyclophosphamid
cy
shown
high
reproduc
accept
safeti
profil
method
prospect
cohort
analysi
allow
us
collect
data
infect
among
consecut
recipi
haplohsct
affect
variou
hematolog
malign
result
median
followup
month
cumul
incid
viral
infect
confid
interv
ci
day
ci
year
patient
risk
cmv
reactiv
rate
polyomavirusvirusassoci
cystiti
cumul
incid
bacteri
fungal
infect
year
ci
ci
respect
note
invas
fungal
infect
occur
beyond
year
transplant
day
conclus
conclus
despit
high
rate
viral
infect
earli
period
present
data
suggest
satisfactori
infecti
profil
tcell
replet
haplohsct
use
posttranspl
cy
result
may
help
clinician
improv
prophylact
therapeut
antimicrobi
strategi
emerg
haploident
set
one
major
limit
hematopoiet
stem
cell
transplant
haploident
donor
haplohsct
impair
immun
reconstitut
owe
extens
immunosuppress
necessari
overcom
human
leukocyt
antigen
dispar
despit
import
advanc
last
decad
infect
still
mostli
respons
toxic
nonrelaps
mortal
among
transplant
patient
owe
prolong
immunosuppress
relat
chronic
graftversushost
diseas
gvhd
platform
tcell
replet
haplohsct
use
posttranspl
cyclophosphamid
cy
show
low
treatmentrel
mortal
trm
high
feasibl
accept
safeti
profil
type
haplohsct
seem
compar
favor
tcell
deplet
method
term
infecti
complic
explor
topic
report
herein
incid
infect
singlecent
cohort
consecut
patient
receiv
tcell
replet
haplohsct
posttranspl
cy
center
order
provid
use
inform
posttranspl
period
type
emerg
transplant
platform
data
patient
hematolog
malign
underw
haplohsct
april
april
humanita
cancer
center
milan
itali
prospect
collect
use
electron
patient
chart
condit
regimen
myeloabl
reducedintens
nonmyeloabl
nonmyeloabl
condit
consist
cy
mgkgday
intraven
iv
day
fludarabin
mg
day
iv
day
total
bodi
irradi
tbi
cgi
day
two
reducedintens
regimen
administ
thiotepa
mgkg
day
iv
day
fludarabin
mgm
day
iv
day
cy
mgkgday
iv
day
tbi
cgi
day
ii
thiotepa
mg
kgday
iv
day
fludarabin
mgm
day
iv
day
busulfan
mgkgday
iv
day
modifi
sanz
et
al
myeloabl
regimen
consist
thiotepa
mg
kgday
iv
day
fludarabin
mgm
day
iv
day
busulfan
mgkgday
iv
day
patient
receiv
unmanipul
bone
marrow
mobil
peripher
stem
cell
gvhd
prophylaxi
perform
cy
mgkgday
day
tacrolimu
mgday
iv
day
reach
concentr
ngml
cyclosporin
mg
kgday
iv
day
reach
concentr
ngml
day
taper
day
unless
gvhd
occur
mycophenol
mofetil
mgkg
day
oral
day
infect
defin
accord
european
societi
blood
marrow
transplant
avail
http
wwwebmtorgcontentsaboutebmtwhowearescientificcouncildocumentsidwpdefin
onspdf
includ
microbiolog
document
viral
bacteri
fungal
infect
without
laboratori
andor
radiolog
featur
consist
organ
involv
cytomegaloviru
cmv
reactiv
de
novo
infect
diseas
diagnos
report
elsewher
invas
fungal
infect
ifi
classifi
accord
definit
eortcmsg
consensu
group
proven
probabl
ifi
record
data
record
june
patient
studi
approv
local
institut
review
board
antimicrobi
prophylaxi
start
condit
regimen
consist
acyclovir
mg
time
day
levofloxacin
mgday
cotrimoxazol
tablet
per
day
day
tablet
everi
day
resum
hematolog
reconstitut
antifung
prophylaxi
perform
echinocandin
either
caspofungin
micafungin
mgday
day
itraconazol
mgday
iv
administ
unless
contraind
otherwis
echinocandin
maintain
septemb
echinocandin
maintain
patient
acyclovir
levofloxacin
antifung
prophylaxi
administ
engraft
occur
twice
weekli
blood
polymeras
chain
reaction
pcr
cmv
monitor
start
day
day
weekli
day
clinic
indic
weekli
epsteinbarr
viru
ebv
monitor
pcr
start
day
day
clinic
indic
test
perform
whenev
indic
piperacillintazobactam
alon
combin
aminoglycosid
administ
empir
therapi
febril
neutropenia
unless
previou
colon
resist
bacteria
document
case
appropri
antibacteri
agent
deliv
true
suspect
bacteri
infect
occur
except
pneumonia
linezolid
ad
combin
abovecit
antibacteri
drug
firstlin
preemptiv
therapi
cmv
infectionreactiv
intraven
ganciclovir
wherea
foscarnet
administ
patient
aplasia
ebv
reactiv
polyomavirusrel
hemorrhag
cystiti
treat
rituximab
cidofovir
respect
threshold
cmv
viremia
initi
therapi
copiesml
threshold
ebv
viremia
copiesml
analysi
circul
lymphocyt
perform
regular
interv
whenev
avail
day
everi
month
afterward
follow
transplant
infecti
diseas
monoclon
antibodi
combin
use
beckman
coulter
fullerton
california
usa
quantifi
b
nk
cell
compart
differ
time
point
studi
categor
variabl
express
absolut
number
respect
percentag
continu
variabl
median
respect
rang
cumul
incid
viral
bacteri
fungal
infect
calcul
use
compet
risk
analysi
start
day
day
first
infect
death
consid
compet
event
infect
incid
also
express
patientday
ptday
time
period
within
year
transplant
interv
defin
follow
day
owe
pauciti
late
event
data
beyond
day
collect
singularli
classifi
accord
pathogen
group
neutrophil
engraft
defin
first
consecut
day
persist
count
l
platelet
engraft
defin
first
consecut
day
persist
count
l
http
portal
kaplanmei
method
use
comput
overal
surviv
cumul
incid
trm
acut
chronic
gvhd
calcul
use
compet
risk
analysi
death
document
infect
defin
infectionrel
death
logrank
test
use
compar
incid
infect
flow
cytometri
result
seventi
consecut
adult
patient
undergo
haplohsct
identifi
main
patient
transplant
characterist
shown
tabl
fiftyf
patient
affect
lymphoma
patient
underw
haplohsct
partial
complet
remiss
patientdonor
pair
cmv
concern
antifung
prophylaxi
patient
receiv
itraconazol
owe
moder
increas
pretranspl
liver
function
test
n
reduct
left
ventricular
eject
fraction
n
patient
receiv
itraconazol
haplohsct
perform
septemb
three
patient
receiv
secondari
antifung
prophylaxi
voriconazol
previou
pulmonari
aspergillosi
median
followup
live
patient
month
rang
day
stem
cell
infus
last
followup
total
document
infecti
event
occur
among
patient
median
eventspati
rang
viral
origin
n
bacteri
n
fungal
n
cumul
incid
first
viral
infect
confid
interv
ci
ci
day
respect
day
incid
bacteri
infect
ci
ifi
ci
fig
patient
risk
least
cmv
reactiv
develop
patient
cmv
reactiv
patient
total
cmv
reactiv
respect
two
nonfat
coliti
pneumonia
fatal
pneumonia
cmv
diseas
occur
primari
cmv
infect
occur
cmv
patientdonor
pair
polyomavirusrel
hemorrhag
cystiti
observ
patient
caus
bk
viru
jc
viru
importantli
ebvrel
lymphoprolif
disord
occur
far
fortyf
patient
present
least
document
bacteri
infect
patient
infect
gramposit
gramneg
type
bacteria
respect
eleven
ifi
detect
patient
n
probabl
invas
aspergillosi
pneumonia
patient
sinus
n
invas
candidiasi
nonalbican
candida
candidemia
coliti
hepatosplen
candidiasi
median
occurr
day
haplohsct
rang
among
patient
receiv
secondari
antifung
prophylaxi
nonalbican
candida
coliti
observ
day
patient
ifi
occur
activ
gvhd
notabl
ifi
occur
beyond
day
pulmonari
aspergillosi
day
candidemia
day
latter
patient
salvag
treatment
posttranspl
relaps
detail
etiolog
report
tabl
observ
signific
differ
infecti
event
accord
condit
regimen
administ
data
shown
consid
time
episod
bacteri
infect
occur
mostli
day
wherea
viral
infect
reactiv
day
bacteri
ptday
day
viral
ptday
day
fig
overal
incid
viral
event
day
day
ptday
total
bacteri
viral
infect
observ
year
transplant
engraft
rate
patient
median
day
rang
day
rang
neutrophil
platelet
recoveri
respect
four
patient
die
engraft
day
gramneg
sepsi
multiorgan
failur
progress
diseas
bacteri
pneumonia
respect
present
primari
antibodylink
graft
failur
aliv
last
followup
autolog
reconstitut
day
cumul
incid
acut
grade
gvhd
ci
ci
respect
chronic
gvhd
ci
twoyear
overal
surviv
ci
trm
ci
patient
relaps
progress
haplohsct
infectionrel
death
occur
day
bacteri
pneumonia
gramneg
sepsi
cmv
pneumonia
pneumonia
jc
virusrel
progress
multifoc
leukoencephalopathi
noninfecti
caus
trm
heart
failur
n
secondari
malign
n
myelodysplast
syndrom
n
esophag
cancer
multiorgan
failur
n
thrombot
microangiopathi
n
acut
hepat
n
last
followup
patient
aliv
complet
remiss
immunophenotyp
analysi
reveal
progress
increas
lymphocyt
subset
count
day
later
posttransplant
time
point
found
trend
toward
less
viral
infect
incid
among
patient
total
lymphocyt
count
day
hazard
ratio
p
associ
observ
lymphocyt
subset
number
patient
analyz
shown
figur
present
analysi
describ
infecti
complic
unmanipul
tcell
replet
haplohsct
use
posttranspl
cy
consecut
patient
found
asid
high
incid
viral
infectionsreactiv
especi
earli
posttranspl
period
quit
low
incid
late
bacteri
infect
togeth
low
incid
ifi
day
event
overal
observ
present
find
confirm
infecti
profil
better
tcell
replet
vs
tcell
deplet
haplotransplant
lower
incid
infect
observ
day
may
reflect
partial
quit
effect
restor
antimicrobi
immun
posttranspl
period
type
haplohsct
importantli
low
rate
chronic
gvhd
seen
cohort
like
contribut
phenomenon
chronic
gvhd
known
major
risk
factor
late
morbid
mortal
nevertheless
found
unexpect
trm
incid
higher
origin
report
posthsct
cy
may
result
inclus
patient
advanc
diseas
haplohsct
program
center
concern
viral
infect
result
line
previou
public
set
tcell
replet
haploident
transplant
ciurea
et
al
report
ptday
within
first
month
transplant
vs
ptday
day
hand
raiola
et
al
found
patient
present
viral
infect
first
year
cmv
reactiv
found
compar
report
similar
haploident
set
slightli
higher
incid
found
may
explain
longer
followup
seri
polyomavirusassoci
cystiti
rate
lower
report
myeloabl
set
like
differ
condit
regimen
cohort
although
role
play
differ
gvhd
prophylaxi
exclud
inde
bk
viru
nephropathi
found
frequent
associ
tacrolimu
cyclosporin
recipi
kidney
allograft
quarter
patient
receiv
cyclosporin
gvhd
prophylaxi
interestingli
confirm
lack
ebvrel
lymphoprolif
disord
recent
report
also
kanakri
et
al
found
incid
fungal
infect
none
fatal
import
note
fatal
episod
fungal
infect
among
major
limit
toxic
associ
tcell
deplet
haplohsct
exclud
role
play
use
antimold
prophylaxi
marrow
aplasia
although
difficult
draw
definit
conclus
owe
lack
true
control
arm
studi
low
number
ifi
note
observ
ifi
month
transplant
concern
bacteri
infect
may
explain
low
preval
late
bacteri
infect
ie
beyond
year
surpris
incid
chronic
gvhd
fact
risk
bacteri
event
remain
low
absenc
late
immunosuppress
therapi
median
followup
month
observ
late
bacteri
event
total
patient
least
year
observ
last
observ
day
month
haplohsct
inform
argu
favor
fact
give
tcell
replet
graft
without
deep
vivo
tdeplet
ie
antithymocyt
globulin
alemtuzumab
posttranspl
cy
allow
satisfactori
infecti
profil
transplant
posttranspl
highdos
cy
permit
naiv
nonactiv
memori
cell
reconstitut
immun
system
later
enabl
patient
protect
late
infecti
event
mechan
probabl
also
explain
high
viral
reactiv
incid
found
first
month
owe
low
number
adopt
transfer
memori
cell
earli
phase
transplant
lugli
e
et
al
unpublish
data
acknowledg
potenti
select
bia
may
present
studi
exclud
possibl
nonsever
late
infect
captur
incomplet
report
howev
patient
follow
institut
therefor
unlik
clinic
relev
infecti
complic
miss
moreov
diagnost
procedur
prophylact
measur
similar
patient
thu
contribut
accuraci
diagnosi
infecti
event
conclus
present
singlecent
data
consecut
patient
receiv
tcell
replet
haplohsct
posttranspl
cy
confirm
high
rate
viral
infect
day
lower
incid
infect
afterward
suggest
satisfactori
although
nonoptim
immun
reconstitut
type
transplant
futur
comparison
haploident
platform
andor
altern
stem
cell
sourc
ie
cord
blood
well
investig
novel
strategi
transfer
immun
warrant
furthermor
present
data
may
provid
use
inform
attempt
improv
control
infect
adequ
prophylaxi
andor
antimicrobi
therapi
earli
posttranspl
period
use
emerg
transplant
platform
haplohsct
